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Echocardiography, Natriuretic Peptides, and
Risk for Incident Heart Failure in Older Adults
The Cardiovascular Health Study
Andreas P. Kalogeropoulos, MD,* Vasiliki V. Georgiopoulou, MD,* Christopher R. deFilippi, MD,†
John S. Gottdiener, MD,† Javed Butler, MD, MPH,* for the Cardiovascular Health Study
Atlanta, Georgia; and Baltimore, Maryland
O B J E C T I V E S This study sought to examine the potential utility of echocardiography and
N-terminal pro–B-type natriuretic peptide (NT-proBNP) for heart failure (HF) risk stratiﬁcation in concert
with a validated clinical HF risk score in older adults.
B A C KG ROUND Without clinical guidance, echocardiography and natriuretic peptides have sub-
optimal test characteristics for population-wide HF risk stratiﬁcation. However, the value of these tests
has not been examined in concert with a clinical HF risk score.
METHOD S We evaluated the improvement in 5-year HF risk prediction offered by adding an
echocardiographic score and/or NT-proBNP levels to the clinical Health Aging and Body Composition (ABC)
HF risk score (base model) in 3,752 participants of the CHS (Cardiovascular Health Study) (age 72.6  5.4
years; 40.8% men; 86.5% white). The echocardiographic score was derived as the weighted sum of independent
echocardiographic predictors of HF. We assessed changes in Bayesian information criterion (BIC), C index,
integrated discrimination improvement (IDI), and net reclassiﬁcation improvement (NRI). We examined also the
weighted NRI across baseline HF risk categories under multiple scenarios of event versus nonevent weighting.
R E S U L T S Reduced left ventricular ejection fraction, abnormal E/A ratio, enlarged left atrium, and increased
left ventricular mass were independent echocardiographic predictors of HF. Adding the echocardiographic score
and NT-proBNP levels to the clinical model improved BIC (echocardiography:43, NT-proBNP:64.1, combined:
68.9; all p  0.001) and C index (baseline: 0.746; echocardiography: 0.031, NT-proBNP: 0.027, combined:
0.043; all p  0.01), and yielded robust IDI (echocardiography: 43.3%, NT-proBNP: 42.2%, combined: 61.7%; all
p 0.001), andNRI (based onHealth ABCHF risk groups; echocardiography: 11.3%; NT-proBNP: 10.6%, combined:
16.3%; all p 0.01). Participants at intermediate risk by the clinical model (5% to 20% 5-yr HF risk; 35.7% of the
cohort) derived the most reclassiﬁcation beneﬁt. Echocardiography yielded modest reclassiﬁcation when used
sequentially after NT-proBNP.
CONC L U S I O N S In older adults, echocardiography and NT-proBNP offer signiﬁcant HF risk
reclassiﬁcation over a clinical prediction model, especially for intermediate-risk individuals. (J Am Coll
Cardiol Img 2012;5:131–40) © 2012 by the American College of Cardiology Foundation
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132ubclinical changes in cardiac structure and
function, including left ventricular (LV) hy-
pertrophy, enlargement, wall motion abnor-
malities, diastolic dysfunction, or reduced
ejection fraction (EF), and left atrial enlargement,
often precede development of manifest (Stage C)
heart failure (HF) (1). These changes, detected
mostly through echocardiography, have been
strongly associated with HF risk in large cohort
studies (2–7). Similarly, elevated natriuretic peptide
levels are associated with structural and functional
cardiac abnormalities (8), and in turn, with HF risk
(8–11). However, the value of echocardiography
See page 141
and natriuretic peptides for HF risk stratification has not
been assessed in concert with a validated clinical risk
score. Moreover, due to suboptimal test char-
acteristics from a screening perspective, and
concerns regarding costs and consequences of
unnecessary testing (4,12–16), these tests are
not recommended currently as standalone
tools for identification of individuals at high
risk for HF. However, guidance by a clinical
risk score, for example, the Health Aging and
Body Composition (Health ABC) HF risk
score (17,18), may render these tests more
appealing as risk stratification tools for targeted
population groups.
We hypothesized that echocardiography
and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels, used individually or in
combination (simultaneously or sequentially),
will have incremental predictive value over the
clinical Health ABC HF risk score for 5-year HF risk
assessment in older adults and yield clinically relevant risk
reclassification. To evaluate this hypothesis, we analyzed
data from 3,752 participants of CHS (Cardiovascular
Health Study) with available echocardiography and NT-
proBNP data.
M E T H O D S
Study population. The design of CHS has been
reviously published (19). Participants were nonin-
from the NIA, HL-075366 from NHLBI, and the University of Pittsburg
Center P30-AG-024827. This project was also partially funded by an
entitled “Novel Risk Markers and Prognosis Determination in Heart Fail
from the Clinical and Translational Science Award program, National Institu
All authors have reported that they have no relationships relevant to the cont
ion
ion
deManuscript received July 11, 2011; revised manuscript received October 20,titutionalized persons 65 to 100 years old, recruited
rom Medicare eligibility lists. An original cohort of
,201 persons was recruited in 1989 to 1990, and a
econd cohort of 687 African Americans was re-
ruited in 1992 to 1993. The present study included
articipants with available baseline NT-proBNP
evels and echocardiographic data, obtained at base-
ine for the original cohort and at year 2 for the
econd cohort. From the 4,522 participants with
vailable baseline NT-proBNP levels, we excluded:
) participants with prevalent HF at baseline (n 
12) and those from the second cohort with prev-
lent HF at year 2 (n  35); 2) those with missing
ata on Health ABC HF risk score variables (n 
62); and 3) those with missing data on echocardi-
graphy (n  361). In all, 3,752 participants were
ncluded in the primary analysis. In a secondary
nalysis, we examined 2,538 participants with avail-
ble quantitative M-mode data on LV dimensions
nd mass.
Deﬁnition of risk factors and Health ABC HF score. We
calculated the Health ABC HF risk score and
categorized participants into5%, 5% to 10%, 10%
to 20%, and 20% 5-year HF risk, as previously
described (17,18). To incorporate the second CHS
cohort, we calculated the score at baseline for these
participants; however, echocardiography for these
participants was available at year 2. For calculation
of Health ABC HF risk score, classification of
prevalent coronary heart disease was based on self-
report of coronary revascularization, myocardial in-
farction, or angina (20). Smoking was classified as
current, past, or never. The Minnesota 3.1 code was
used to classify electrocardiographic LV hypertro-
phy (21). The core laboratory at University of
Vermont, Colchester, Vermont, analyzed fasting
serum chemistry.
Echocardiographic assessment in CHS. Two-dimen-
ional echocardiography was performed at baseline
or the original cohort and at year 2 for the second
ohort. Studies were centrally interpreted at the
niversity of California, Irvine (22). We classified
V systolic function as normal, borderline, or ab-
ormal, corresponding to EF 0.55, 0.45 to 0.54,
nd 0.45, respectively (23). Based on previous
ndings from CHS showing values 0.7 and 1.5
laude D. Pepper Older Americans Independence
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133to be associated with increased HF risk (4), the
mitral inflow E to A peak velocity ratio (E/A ratio)
was classified into 0.7, 0.7 to 1.5, and 1.5. Left
trial enlargement was based on American Society of
chocardiography recommended M-mode anteropos-
erior diameter of 23 mm/m2 (24). Quantitative
V M-mode measurements were available in 3,410
articipants of the original cohort, with age being
he strongest correlate of missing data (23), and 405
articipants of the second cohort. LV mass was
alculated with the Devereux formula (25). To
efine LV hypertrophy and enlargement, we used
ender-specific cutoffs proposed by the American
ociety of Echocardiography: 95 g/m2 for women
nd 115 g/m2 for men for LV mass; and 32
m/m2 for women and 31 mm/m2 for men for
V diameter at diastole (24).
Natriuretic peptide assay. NT-proBNP was mea-
sured with the Elecsys 2010 system (Roche Diag-
nostics, Indianapolis, Indiana) in serum collected at
baseline. Coefficient of variation was 2% to 5%, and
range was 5 to 35,000 pg/ml. In a previous analysis
from CHS (9), NT-proBNP190 pg/ml optimally
predicted HF risk and cardiovascular mortality; we
therefore used this cutoff for additional analyses.
Deﬁnition of incident HF. Methods used to assess
ardiovascular events in CHS, including HF, have
een reported previously (26,27). An HF event was
onfirmed if, in addition to a physician diagnosis,
here were: 1) documented symptoms (e.g., short-
ess of breath, fatigue, orthopnea, paroxysmal noc-
urnal dyspnea) and physical signs (e.g., edema,
ulmonary rales, gallop rhythm) consistent with
F; 2) supporting clinical findings such as pulmo-
ary edema on chest x-ray; or 3) therapy for HF,
ncluding diuretics, digitalis, angiotensin-converting en-
yme inhibitors, or beta-blockers. In the current
nalysis, incident HF was defined as adjudicated
rst hospitalization for HF.
Statistical analysis. NT-proBNP values were log-
transformed before analyses because of lognormal
distribution. To identify echocardiographic vari-
ables that predict HF independently of clinical risk
factors, we used the Health ABC HF risk score as
a covariate in multivariable Cox proportional haz-
ards models and followed an iterative, clinically
guided approach to reach the final echocardiography-
added model. The final set of echocardiographic
predictors was treated subsequently as a single score
(weighted sum of covariates) to assess model
improvement.
To assess the incremental value of NT-proBNP
and echocardiographic score for 5-year HF riskprediction, we used Health ABC HF risk score as
the base clinical model and calculated: 1) changes in
the Bayesian information criterion (BIC), a
likelihood-based measure of model fit that penalizes
for complexity (28); 2) changes in the C index;
3) the integrated discrimination improvement
(IDI), which quantifies improvement in prognostic
separation (29,30), and relative IDI (rIDI), which
quantifies the relative contribution of an added
variable to separation (30); and 4) the net reclassi-
fication improvement (NRI), a clinically oriented
measure of reclassification that considers any cor-
rect upwards movement of events (in the new vs.
the old model) and any downwards movement of
non-events as model improvement and vice versa
(29). To facilitate prospective interpretation, we
used the censored data versions of IDI (31) and
NRI (32). The Kaplan-Meier estimates for 5-year
HF incidence served as observed event rates. We
calculated the continuous NRI, which counts all
movements of probabilities and does not rely on
categories (NRI0), and the NRI based on 5-year
risk groups (i.e.,5%, 5% to 10%, 10% to 20%, and
20%) (17), which counts only movements of
predicted probabilities that result in a change in risk
category (NRIcat). Because event and non-event
NRI components are weighted by event incidence
(32), and thus NRI is not comparable across risk
categories, we calculated the weighted NRI for
events and non-events (wNRI) (32) to compare
reclassification across baseline risk categories. Cur-
rently, no established thresholds for action regard-
ing HF risk exist, and thus, the relative merit of
correctly classifying an event versus a non-event is
unknown. We thus calculated wNRI by assigning
weights from 1:1 (equal importance) to 16:1 (events
16 more important). The NRI formulas (NRI0,
RIcat, and wNRI) are provided in the Online
ppendix and Online Table 1.
To examine the incremental value of NT-
roBNP and echocardiographic score for risk pre-
iction among participants with normal left ven-
ricular ejection fraction (LVEF) at baseline, we
eplicated the analyses in the subcohort of partici-
ants with LVEF 0.55. Analyses were performed
ith STATA version 11 (StataCorp LP, College
tation, Texas).
R E S U L T S
Clinical characteristics and HF incidence. Average age
was 72.6  5.4 years; 40.8% were men; 86.5% were
white. Table 1 summarizes the clinical characteris-
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134tics of participants by Health ABC HF risk group.
There were 286 incident HF events during the first
5 years of follow-up, corresponding to 8.0% 5-year
HF incidence.
Echocardiographic ﬁndings and NT-proBNP levels.
Figure 1 presents the prevalence of echocardio-
Table 1. Baseline Clinical Characteristics According to Health AB
<5%
(n  2,228)
Age, yrs 70.6 (3.9)
Men, % 34.0
White, % 88.5
Smoking, %
Current 6.3
Former 42.3
Coronary heart disease 3.4
Left ventricular hypertrophy, %* 1.2
Systolic blood pressure, mm Hg 129 (17)
Heart rate, beats/min 63 (10)
Creatinine, mg/dl 0.97 (0.23)
Fasting glucose, mg/dl 105 (22)
Albumin, g/dl 4.04 (0.28)
Total cholesterol, mg/dl 215 (38)
Values are n (%) or %. *By electrocardiography.
ABC  Aging and Body Composition; HF  heart failure.
Figure 1. Abnormal Echocardiographic Findings According to P
Prevalence of abnormal echocardiographic ﬁndings according to pr
(HF) at baseline. M-mode left ventricular diameter and mass were a
mm/m2 (24). †Indexed internal diameter at diastole 32 mm/m2 fo
95 g/m2 for women, 115 g/m2 for men (24). Parameters indexe
for all parameters.graphic abnormalities according to clinically pro-
jected HF risk by the Health ABC HF risk score.
Left atrial diameter, LV diameters, and LV mass,
all had strong increasing trends across Health ABC
HF risk groups (Table 2). Abnormal EF (0.45%)
or restrictive-type diastolic (E/A 1.5) dysfunction
F Risk Group
Health ABC 5-yr HF Risk
5%–10%
(n  907)
10%–20%
(n  433)
>20%
(n  184)
74.4 (5.4) 76.5 (6.0) 79.3 (6.9)
48.2 56.1 51.6
83.7 83.8 82.6
15.3 16.4 22.8
42.1 41.8 33.2
25.3 50.8 66.9
3.9 11.5 24.5
143 (21) 149 (23) 158 (25)
66 (12) 68 (13) 74 (18)
1.09 (0.28) 1.21 (0.39) 1.38 (0.64)
117 (40) 125 (46) 139 (85)
3.97 (0.28) 3.96 (0.30) 3.86 (0.28)
211 (40) 206 (39) 206 (43)
cted HF Risk
ted Health ABC HF risk in 3,752 participants without heart failure
ble in 2,538 participants. *Indexed left atrial diameter 23
men, 31 mm/m2 for men (24). ‡Indexed left ventricular mass
r body surface area. p  0.001 for linear trend across categoriesC Hroje
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135was present in 5.8%, 6.5%, 11.5%, and 16.8% of
participants in the escalating HF risk groups, re-
spectively. Absolute NT-proBNP levels and preva-
lence of increased (190 pg/ml) NT-proBNP lev-
els both had strong increasing trends across clinical
HF risk groups (Fig. 2).
Echocardiographic parameters, NT-proBNP, and HF risk
prediction. Among the echocardiographic parame-
ers examined, EF, enlarged left atrium, and E/A
atio were independent predictors of HF risk when
dded to Health ABC HF risk score (Table 3). In
he subset with M-mode data on LV dimensions
nd mass available (n  2,538), LV fractional
hortening was a stronger predictor than EF, and
V mass index was an additional independent
redictor of HF (Table 3). The weighted sum of
chocardiographic parameters constituted the echo-
ardiographic score used subsequently to determine
isk stratification improvement. For completeness,
e have created separate scores for the main cohort
EF, enlarged left atrium, and E/A ratio) and for
he quantitative LV subset (fractional shortening,
nlarged left atrium, and E/A ratio, LV mass) to
est for incremental value, although only the main
ohort parameters were converted to a point system
or practical use.
Table 2. Quantitative Echocardiographic Characteristics Accordi
N <5%
Left atrial diameter index, mm/m2 3,752 21.2 (3.5)
LV diastolic diameter index, mm/m2 2,538 27.3 (3.4)
LV systolic diameter index, mm/m2 2,538 15.6 (3.1)
LV mass index, g/m2 2,538 79 (20)
Values are n (%).
LV  left ventricular; other abbreviations as in Table 1.
Figure 2. NT-proBNP Levels According to Projected HF Risk
Distribution of N-terminal pro–B-type natriuretic peptide (NT-proBN
NT-proBNP levels (right) according to projected Health ABC HF risk
HF  heart failure.NT-proBNP levels were independently associ-
ted with 5-year HF risk when added to Health
BC HF risk score; hazard ratio per natural log-
ncrease of NT-proBNP was 1.61 (95% confidence
nterval: 1.44 to 1.81; p  0.001). Increased NT-
roBNP as a binary variable (190 pg/ml) was
ssociated with 2.7-fold increased risk (95% confi-
ence interval: 2.1 to 3.6; p  0.001).
Both NT-proBNP and echocardiographic score
ignificantly improved fit, discrimination, and risk
lassification when added to Health ABC HF risk
core (Table 4). Combined NT-proBNP and echo-
ardiography had further incremental value over each
odality alone, achieving further improvements in
ntegrated discrimination (0.064, or 61.7% relative
ncrease) and net reclassification (35.9% for continu-
us NRI and 16.3% for category-based NRI). The
mpact of echocardiography was stronger when quan-
itative LV parameters were considered (Table 4).
When the echocardiographic score was used sequen-
ially after adding NT-proBNP to the base model, it still
rovided significant but less robust improvements in
ntegrated discrimination (0.019, or 12.8% relative in-
rease) and net reclassification (20.0% for continuous
RI and 7.9% for category-based NRI; both p 0.01).
n the subset with quantitative LV data, echocardiogra-
o Health ABC HF Risk
Health ABC 5-Year HF Risk
5%–10% 10%–20% >20% p for Trend
21.5 (3.8) 22.2 (4.3) 23.0 (4.3) 0.001
27.4 (3.8) 27.8 (4.0) 28.2 (4.6) 0.024
16.2 (3.6) 16.6 (4.3) 17.2 (4.5) 0.001
85 (23) 93 (30) 94 (33) 0.001
vels (left) and prevalence of increased (190 pg/ml) (9)
0.001 for linear trend across categories in both analyses.ng tP) le
. p 
nl
d
1
o

a
d
tions
relative integrated discrim
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136phy further improved classification compared to the
NT-proBNP–added model (0.041, or 30.1% for IDI;
31.0% for continuous NRI [p  0.001]; and 13.2% for
category-based NRI [p  0.01]).
Reclassiﬁcation of HF risk according to baseline HF risk
group. In participants with 5% projected risk,
either echocardiographic score nor NT-proBNP
Table 3. Echocardiographic Predictors of Incident HF
HR (95%
Main cohort (n  3,752)
LV ejection fraction
Borderline (0.45 to 0.54) 1.20 (0.76–1
Abnormal (0.45) 3.48 (2.35–5
E/A ratio
0.7 1.61 (1.24–2
1.5 3.23 (2.25–4
Enlarged LA (23 mm/m2) 1.60 (1.27–2
Wall motion abnormalities (yes, no) 1.54 (1.13–2
Quantitative LV subset (n  2,538)
LV ejection fraction
Borderline (0.45 to 0.54) 1.47 (0.84–2
Abnormal (0.45) 3.78 (2.22–6
LV fractional shortening, per 5% decrease 1.23 (1.13–1
E/A ratio
0.7 1.98 (1.42–2
1.5 3.27 (2.08–5
Enlarged LA (23 mm/m2) 1.55 (1.15–2
LV end-diastolic diameter, per cm/m2 1.69 (1.18–2
LV end-systolic diameter, per cm/m2 2.40 (1.71–3
LV mass index, per 10 g/m2 1.16 (1.10–1
*Adjusted for Health ABC HF Risk Score.
CI  conﬁdence interval; HR  hazard ratio; LA  left atrium; other abbrevia
of Echocardiographic Score and NT-proBNP for HF Risk Predicti
BIC
p Value
(BIC) C
p Value
(C)
2)
e 4,424.8 Reference 0.746 Reference
ded 4,381.8 0.001 0.777 0.001 0
4,360.7 0.001 0.773 0.004 0
d 4,355.9 0.001 0.789 0.001 0
(n  2,538)
2,607.5 Reference 0.744 Reference
ded 2,532.2 0.001 0.798 0.001 0
2,570.1 0.001 0.774 0.014 0
d 2,520.1 0.001 0.805 0.001 0
improvement. NRI0 represents continuous NRI, which counts any movement of p
ly movements that result in change in risk category.
on criterion; IDI  integrated discrimination improvement; NRI  net reclassiﬁca
ination improvement; other abbreviations as in Tables 1 and 2.evel provided clinically relevant reclassification un-
er a wide range of scenarios (Fig. 3). In the 5% to
0% category, clinically relevant reclassification was
bserved both with echocardiography (wNRI
15%) and NT-proBNP (wNRI 10%) across
ssigned weights. The 10% to 20% HF risk category
erived the most reclassification benefit both from
variate* Multivariate*
p Value HR (95% CI) p Value
0.43 1.17 (0.74–1.84) 0.50
0.001 2.91 (1.96–4.33) 0.001
0.001 1.56 (1.19–2.03) 0.001
0.001 2.70 (1.87–3.09) 0.001
0.001 1.50 (1.18–1.91) 0.001
0.007 — —
0.17 — —
0.001 — —
0.001 1.16 (1.07–1.27) 0.001
0.001 1.72 (1.22–2.42) 0.002
0.001 2.92 (1.84–4.63) 0.001
0.004 1.42 (1.04–1.93) 0.028
0.005 — —
0.001 — —
0.001 1.11 (1.06–1.17) 0.001
as in Tables 1 and 2.
I (rIDI) NRI0
p Value
(NRI0) NRIcat
p Value
(NRIcat)
ference Reference Reference Reference Reference
4 (42.2%) 31.8% 0.001 10.6% 0.007
5 (43.3%) 31.7% 0.001 11.3% 0.007
4 (61.7%) 35.9% 0.001 16.3% 0.001
ference Reference Reference Reference Reference
6 (53.7%) 39.7% 0.001 18.8% 0.001
3 (32.5%) 26.6% 0.001 12.1% 0.024
5 (72.8%) 50.2% 0.001 24.5% 0.001
ted probabilities; NRIcat is based on 5%, 5% to 10%, 10% to 20%, and 20%
improvement; NT-proBNP  N-terminal pro–B-type natriuretic peptide; rIDI Uni
CI)
.89)
.15)
.10)
.63)
.03)
.11)
.57)
.46)
.34)
.77)
.14)
.08)
.43)
.36)
.21)Table 4. Added Value on
Statistic ID
Main cohort (n  3,75
Health ABC HF Scor Re
Echocardiography ad .04
NT-proBNP added .04
Echocardiography an
NT-proBNP added
.06
Quantitative LV subset
Health ABC HF score Re
Echocardiography ad .05
NT-proBNP added .03
Echocardiography an
NT-proBNP added
.07
rIDI expresses the relative redic
categories, and counts on
BIC  Bayesian informati tion
L
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137echocardiography and NT-proBNP; wNRI was
20% for both modalities regardless of weights
assigned to events versus nonevents. In the 20%
risk category, reclassification gain was evident only
when 1:1 weights were assigned. Modest synergistic
gains were observed when echocardiography and
NT-proBNP were used simultaneously. When risk
was first refined by NT-proBNP, echocardiography
provided gains over the NT-proBNP–added model
(10% wNRI) in the 5% to 10% and 10% to 20%
categories.
Echocardiography and NT-proBNP in participants with
normal LVEF. Among the 3,480 participants with
VEF 0.55, there were 236 incident HF events
uring the first 5 years of follow-up, corresponding
o 7.1% 5-year HF incidence. Both echocardiography
nd NT-proBNP conferred significant reclassification
f HF risk in these participants (Online Table 2).
hen measured by the IDI, the magnitude of reclas-
ification benefit by echocardiography or NT-
Figure 3. NRI by Echocardiography and NT-proBNP According t
Net reclassiﬁcation improvement (NRI) across the Health ABC heart
score (A), N-terminal pro–B-type natriuretic peptide (NT-proBNP) (B
score is added after reﬁnement of risk with NT-proBNP. Five differe
correct reclassiﬁcation of events versus non-events, representing in
is equally important for events and non-events, whereas 16:1 deno
than correct reclassiﬁcation of a non-event. Clinically relevant corre
with echocardiography (A) and NT-proBNP (B) across assigned weig
20% (yellow bars) heart failure risk as clinically determined by the Hea
proBNP and echocardiography were used simultaneously (C). When ris
incremental beneﬁt. wNRI indicates the average weighted NRI, the weroBNP in this subcohort was diminished relative tohat observed in the entire study cohort, because risk
ariance was lower in this relatively healthier subco-
ort. However, both the continuous and the categor-
cal NRI for echocardiography were practically unaf-
ected. NT-proBNP exhibited slightly smaller NRI
alues relative to the entire cohort. In the subset with
uantitative LV measurements and LVEF 0.55
n 2,384), the reclassification properties of echocar-
iography were enhanced.
D I S C U S S I O N
In this study, we demonstrated that echocardiogra-
phy and NT-proBNP could have incremental value
over a validated clinical model for HF risk predic-
tion in older adults. Improvements in HF risk
prediction were not limited to formal improvements
in model fit and discrimination, but also resulted in
clinically relevant risk reclassification among the
35.7% of participants deemed to be at intermedi-
seline HF Risk
re (HF) risk categories with addition of the echocardiographic
both (C) to the Health ABC HF model; (D) echocardiographic
enarios are presented with varying weights (from 1:1 to 16:1) for
sing importance of events: 1:1 denotes that correct reclassiﬁcation
hat correct reclassiﬁcation of an event is 16 times more important
classiﬁcation (indicated by 10% positive bars) was observed
for participants with baseline 5% to 10% (green bars) or 10% to
ABC HF risk score. Modest synergistic gains were observed when NT-
as ﬁrst reﬁned by NT-proBNP (D), echocardiography provided modest
d percentage of participants correctly reclassiﬁed.o Ba
failu
), or
nt sc
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tes t
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1385-year HF risk) by the clinical score. Of note, LV
diastolic function proxy parameters (E/A ratio
and left atrial size) were independent determi-
nants of HF risk in this cohort. The risk reclas-
sification potential of echocardiographic param-
eters and NT-proBNP was also evident among
participants with normal (0.55) LVEF at base-
line. Quantitative assessment of LV mass further
strengthened the value of echocardiography for risk
reclassification; this was more pronounced in par-
ticipants with normal LVEF, potentially because
LV mass plays a central role in HF risk determina-
tion in these individuals.
There is a fundamental difference between
screening for subclinical disease and risk stratifica-
tion for future disease. The detection of the former
is by definition the “end product,” for example,
breast cancer, which necessitates treatment. The
latter needs further evidence for effective prevention
strategies and action thresholds to be clinically
relevant. Currently, besides treatment of asymp-
tomatic LV systolic dysfunction, there are no spe-
cific HF prevention strategies beyond usual risk
factor management, for example, hypertension.
However, most participants who developed HF in
CHS did not have reduced EF at baseline (4), and
the prevalence of asymptomatic LV systolic dys-
function in the community is too low to justify
population-wide screening (16). In fact, even com-
bining abnormal systolic (EF 0.45) or restrictive-
ype diastolic (E/A 1.5) dysfunction would miss
0% of CHS participants who developed HF
ithin 5 years. On the other hand, if all echocar-
iographic predictors in our study (any degree of
V systolic or diastolic dysfunction or left atrial
nlargement) were considered as subclinical disease,
he yield would be too high (43%, 53%, 65%, and
0% for the ordered Health ABC HF risk score
roups) to be clinically meaningful. Thus, screening
or asymptomatic abnormalities is unlikely to be
ery effective by itself for HF prevention in the
eneral population of older adults.
In line with previous studies (4,6,33), the echo-
ardiographic markers associated with HF risk in
ur study were related to both systolic and diastolic
V function. Despite adjustment for the Health
BC HF risk score, which incorporates clinical risk
actors associated with diastolic dysfunction (17),
chocardiographic surrogates of diastolic dysfunc-
ion were strongly associated with HF risk in our
tudy, highlighting the importance of diastolic dys-
unction when considering incorporation of echo-
ardiography in HF prevention efforts (34). Al-hough we cannot suggest that echocardiography be
sed for HF risk stratification at this point, consider-
ng that a number of patients undergo echocardiogra-
hy for other indications, we provide a modification
able for the Health ABC HF risk score based on
chocardiographic findings (Online Table 3).
Similar to echocardiography, most studies have
oncluded that natriuretic peptides are not cost
ffective for detection of asymptomatic structural
eart disease (35,36). This is rooted in the fact that
atriuretic peptides are conceptually used to select
ndividuals for echocardiographic screening (16),
earing all the limitations noted above. Based on
ur results, the effect of echocardiographic screen-
ng on HF prevention would still be modest at best,
ven after NT-proBNP–based selection (16,37).
n the other hand, NT-proBNP refined risk as-
essment in our study, in line with observations
rom younger cohorts (38,39). Currently, no data
upport use of NT-proBNP as a HF risk tool in
nselected older adults. However, our findings un-
erscore the potential of a strategy incorporating
atriuretic peptides for intermediate-risk individu-
ls when considering HF prevention efforts. In this
espect, we provide a practical approach to refine
F risk based on NT-proBNP levels if these are
vailable (Online Table 4).
Abnormal systolic or restrictive-type diastolic LV
ysfunction often has causes amenable to treatment
ischemia, cardiomyopathy, LV hypertrophy, valvu-
ar disease, and so on). Therefore, it might be worth
creening with echocardiography older adults with
rojected 10% to 20% or 20% 5-year HF risk. In
these groups, which combined constituted 16.5% of
our cohort, abnormal systolic or restrictive-type
diastolic dysfunction was present in 11.5% and
16.8%, respectively. Based on analyses showing that
prevalence rates of5% in the target population are
likely to result in cost-effective echocardiographic
screening (37), the Health ABC HF risk score
might serve as a useful selection tool. Similarly,
incorporation of NT-proBNP in the Health ABC
HF risk score for screening selection appears to be
an attractive target for future investigations.
What are the practical implications of our find-
ings? First, there are currently no prevention strat-
egies for individuals at increased HF risk, barring
treatment of asymptomatic LV dysfunction or in-
dividual risk factors. Thus, it is difficult to translate
improvement in HF risk classification into action-
able items or cost-effectiveness gains at this point.
This gap highlights the need for prospective data on
HF prevention strategies. Second, we demonstrated
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139that echocardiographic screening with a “subclinical
disease” approach alone would fail to detect most
patients at risk for HF, even for a 5-year horizon. A
strategy providing HF risk assessment and risk
factor modification based on projected HF risk, and
potentially novel preventive interventions, would
likely be more effective from a population perspec-
tive. Echocardiography and natriuretic peptide test-
ing might be reserved for selected individuals. Such
a strategy, however, would need prospective valida-
tion. Third, extrapolating from the coronary heart
disease prevention paradigm, it may be reasonable
at this point to follow-up more closely individuals at
10% 5-year HF risk, with the aim to intensify risk
factor control, monitor for symptoms, and potentially
screen with echocardiography for LV dysfunction based
on the rationale described in the previous text.
Study limitations. First, definition of incident HF was
ased on admissions and this may have underesti-
ated HF incidence. However, because of central
djudication, underestimation is most likely distrib-
ted evenly across risk groups and thus our reclassifi-
ation estimates should be relatively unbiased. On the
ther hand, we cannot exclude the possibility of
scertainment bias in determining the relative impor-
ance of the echocardiographic measures. Participants
ith possible clinical HF were perhaps more likely to
e admitted if a clinically performed echocardiogram
evealed LV systolic dysfunction (as opposed to iso-
ated left atrial dilatation or increased LV mass). This
ould partly explain why LVEF was strongly associ-
ted with HF risk compared with other echocardio-stroke, congestive heart failure, and Heart J 2008;29:74ardiography was assessed by the E/A ratio and,
ndirectly, by the left atrial volume. These measures do
ot reflect contemporary assessment or classification
f diastolic dysfunction. Third, our study population
omprised of white and black participants, and blacks
ere underrepresented. Thus our findings may not be
pplicable to other races. Finally, we studied partici-
ants age 65 years or older; thus our findings may not
e applicable to younger populations.
C O N C L U S I O N S
Echocardiography and NT-proBNP significantly
reclassify 5-year HF risk in older adults when added
to a clinical model, mainly among intermediate-risk
individuals. A strategy incorporating echocardiog-
raphy or NT-proBNP for these individuals may be
worth investigating prospectively. Echocardiogra-
phy at this point might be reserved for those at
10% projected 5-year HF risk because of the
prevalence of potentially treatable underlying ab-
normalities in this group. However, a strategy based
solely on screening for asymptomatic abnormalities
is unlikely to have dramatic impact on HF preven-
tion in older adults. An alternative strategy, based
on risk stratification and tiered preventive interven-
tions, might be more effective and warrants further
investigation.
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